|
J Biol Chem, Vol. 275, Issue 11, 7764-7770, March 17, 2000
A Rho-related GTPase Is Involved in
Ca2+-dependent Neurotransmitter Exocytosis*
Frédéric
Doussau §,
Stéphane
Gasman¶,
Yann
Humeau ,
Francesco
Vitiello ,
Michel
Popoff**,
Patrice
Boquet ,
Marie-France
Bader¶, and
Bernard
Poulain §§
From the Laboratoire de Neurobiologie
Cellulaire, CNRS, UPR 9009 and ¶ INSERM, U-338 Biologie de la
Communication Cellulaire, F-67084 Strasbourg Cédex,
** Toxines Microbiennes, Institut Pasteur, F-75724 Paris Cédex 15, and  INSERM, U-452 Biologie Cellulaire et
Moléculaire des Microorganismes et de leurs Toxines,
F-06107 Nice Cédex 2, France
 |
ABSTRACT |
Rho, Rac, and Cdc42 monomeric GTPases are well
known regulators of the actin cytoskeleton and phosphoinositide
metabolism and have been implicated in hormone secretion in endocrine
cells. Here, we examine their possible implication in
Ca2+-dependent exocytosis of
neurotransmitters. Using subcellular fractionation procedures, we found
that RhoA, RhoB, Rac1, and Cdc42 are present in rat brain synaptosomes;
however, only Rac1 was associated with highly purified synaptic
vesicles. To determine the synaptic function of these
GTPases, toxins that impair Rho-related proteins were
microinjected into Aplysia neurons. We used lethal toxin
from Clostridium sordellii, which inactivates Rac; toxin B
from Clostridium difficile, which inactivates Rho, Rac, and Cdc42; and C3 exoenzyme from Clostridium botulinum and
cytotoxic necrotizing factor 1 from Escherichia coli, which
mainly affect Rho. Analysis of the toxin effects on evoked
acetylcholine release revealed that a member of the Rho family, most
likely Rac1, was implicated in the control of neurotransmitter release.
Strikingly, blockage of acetylcholine release by lethal toxin and toxin
B could be completely removed in <1 s by high frequency stimulation of
nerve terminals. Further characterization of the inhibitory action
produced by lethal toxin suggests that Rac1 protein regulates a late
step in Ca2+-dependent neuroexocytosis.
 |
INTRODUCTION |
Rho proteins form a subfamily of highly conserved small GTPases
belonging to the Ras superfamily. In mammals, Rho GTPases comprise Rho
(A to H isoforms), Rac (Rac1 and Rac2 isoforms), Cdc42 (Cdc42Hs and
G25K isoforms), and more distant members. Like other monomeric GTPases
of the Ras family, Rho proteins act as molecular switches: upon
receiving upstream signals, they are converted into an active GTP-bound
form that is able to interact with downstream effectors. These comprise
protein kinase N, Rho kinase, phosphatidylinositol 3-kinase,
phosphatidylinositol 4-kinase, phosphatidylinositol 5-kinase, and the
myosin-binding subunit of myosin phosphatase (for review, see Ref. 1).
In fine, the activation of Rho-related GTPases leads mainly
to a rearrangement of the actin-based cytoskeleton and/or to a
regulation of phosphoinositide levels. Rho proteins have been
implicated in a large variety of cellular functions, including
chemotaxis, cell cycle progression, axonal guidance. and endocytosis
(for review, see Refs. 1-3).
Ca2+-triggered neurotransmitter release and hormone
secretion are closely related mechanisms that involve proteins common
to both neurons and secretory cells. For example, synaptobrevin, syntaxin, 25-kDa synaptosomal-associated protein, synaptotagmin, soluble N-ethylmaleimide-sensitive factor, and soluble
N-ethylmaleimide-sensitive factor attached proteins act in
concert to ensure docking and/or fusion in both dense-core granule and
synaptic vesicle exocytosis. Consistent with the implication of Rab
proteins in vesicle trafficking, the small GTPase Rab3 has been
shown to regulate both neurotransmitter and hormone secretion (for
review, see Refs. 4-10). On the other hand, despite the similarities
between the release of the content of synaptic vesicles and large
dense-core granules, several recent studies have revealed mechanistic
differences between these two exocytotic processes (for review, see
Refs. 7 and 11).
In endocrine cells, members of the Rho family have been proposed to
regulate exocytosis. Indeed, Cdc42 and Rac control regulated secretion
in pancreatic beta cells (12), basophilic leukemia cells (13), and mast
cells (14). In chromaffin cells, RhoA localized on secretory granules
controls subplasmalemmal actin and exocytosis by regulating a
granule-associated phosphatidylinositol 4-kinase (15, 16). Rho-like
GTPases have been implicated in actin filament dynamics and organelle
movement in growth cones (for review, see Ref. 17). The aim of our
study was to probe the presence of Rho proteins in nerve terminals and
to determine their possible implication in neurotransmitter release.
We found that Rac1, RhoA, RhoB, and Cdc42 are present in nerve
terminals, with Rac1 selectively associated with purified synaptic vesicles. The role played by these small GTPases in neurotransmission was addressed by monitoring acetylcholine
(ACh)1 release from
identified cholinergic neurons in the Aplysia buccal ganglion. The function of Rho-related GTPases was impaired by presynaptic microinjection of bacterial toxins known to selectively activate or inactivate subgroups of Rho proteins (for review, see Ref.
18). Our results suggest that a Rho-related protein, most likely Rac1,
plays a major role in neurotransmission by controlling a yet undefined
Ca2+-dependent late step of synaptic vesicle exocytosis.
 |
EXPERIMENTAL PROCEDURES |
Toxin Preparation--
Lethal toxin (LT) from Clostridium
sordellii strain IP82 was purified as described previously (19).
Recombinant C3 exoenzyme was expressed in Escherichia coli
strain Sure (Stratagene) from pMRP143, consisting of the DNA fragment
coding for the mature C3 protein (20) under the control of the iota
toxin gene promoter in vector pJIR750 (21). After sonicating bacterial
cells in 10 mM Tris-HCl (pH 8.5), the extract was clarified
by centrifugation, treated with protamine sulfate (2 mg/ml; Merck) for
30 min at 40 °C, and centrifuged again. The supernatant was loaded
onto a QAE-Sepharose A50 column (Amersham Pharmacia Biotech)
equilibrated in 10 mM Tris-HCl (pH 8.5). The flow-through
containing the purified C3 enzyme showed a single band of 25 kDa on
SDS-polyacrylamide gel electrophoresis. Cytotoxic necrotizing factor 1 (CNF1), a 110-kDa protein toxin from pathogenic E. coli
strains, was purified as described previously (22, 23). Stock solutions
(20 µM) were prepared in 50 µM Tris-HCl (pH
7.4) containing 100 µM NaCl. A recombinant C-terminal
14.8-31.5 kDa peptide corresponding to the catalytic region of CNF1
was produced as a glutathione S-transferase fusion protein.
It was purified according to a previously described procedure (24). A
stock solution (20 µM) was prepared in sodium phosphate
buffer (pH 7.4) containing reduced glutathione (20 mM). All
toxins were stored at 80 °C in 3-5-µl aliquots. The various buffers used for storage of the toxins had no effect on evoked ACh release.
The biological activity of each batch of toxin was verified by the
ability to induce morphological changes and cytoskeletal modifications
(C3, ToxB, and LT: cell rounding and disruption of stress fibers; and
CNF1: cell spreading and increase in stress fibers), visualized by
staining of HeLa or Vero cells with fluorescein-conjugated phalloidin
(22, 23, 25). The activity of C3 was further determined by its ability
to induce [32P]ADP-ribosylation of membrane-bound RhoA
present in purified chromaffin granule preparations (15). The enzymatic
activity of CNF1 on recombinant RhoA (22) or chromaffin
granule-associated RhoA (data not shown) was demonstrated by an
increase in the apparent molecular mass of the molecule on SDS gels.
Isolation and Fractionation of Synaptic Vesicles from Rat
Brain--
Synaptic vesicles were prepared from rat brains according
to Huttner et al. (26). Briefly, 14 rat brains were placed
in ice-cold buffered sucrose (320 mM sucrose and 4 mM Hepes-NaOH (pH 7.4)). From this point on, the material
was kept at 4 °C. Cerebral cortices were dissected free of
cerebellum, brainstem, and most of the midbrain and homogenized in the
same buffer containing 1 µM phenylmethylsulfonyl fluoride
and 2 µg/ml pepstatin in a Teflon/glass homogenizer. The homogenate
was then centrifuged for 10 min at 1100 × g. The
resulting supernatant was centrifuged for 15 min at 9200 × g, and the pellet was resuspended in 10 ml of buffered
sucrose/brain and centrifuged for 15 min at 10,500 × g. The resulting pellet (synaptosomes) was resuspended in
buffered sucrose, diluted with 9 volumes of ice-cold H2O
(hypotonic lysis of synaptosomes), and immediately homogenized.
Protease inhibitors (pepstatin and phenylmethylsulfonyl fluoride) and 1 M Hepes (pH 7.4) at a final concentration of 7.5 mM were added, and the homogenate was incubated on ice for
30 min and then centrifuged for 20 min at 25,500 × g.
The pellet containing synaptosomal membranes (i.e. plasma
membrane, mitochondria, and granules) was saved. The supernatant was
centrifuged for 2 h at 48,000 rpm in a Ti-60 rotor (Beckman Instruments). The resulting supernatant was cleared by centrifugation at 100,000 × g and saved (cytosol). The pellet (crude
synaptic vesicles) was resuspended in 4 ml of 30 mM sucrose
and 4 mM Hepes (pH 7.4), homogenized, passed five times
back and forth through a 25-gauge needle, loaded on a continuous
gradient of 50-800 mM sucrose in 4 mM Hepes
(pH 7.4), and centrifuged for 5 h at 26,000 rpm in an SW 28 rotor
(Beckman Instruments). After centrifugation, 2-ml fractions were
collected. Fractions in the 200-400 mM sucrose region were
pooled and chromatographed on a glyceryl-coated controlled-pore glass
bead column (GLY 03000B, Electro-Nucleonics Inc.) to obtain highly
purified synaptic vesicles (26). Protein content of the various
fractions was analyzed by the Bradford procedure (Bio-Rad).
Gel Electrophoresis and Immunoblotting--
SDS-polyacrylamide
gel electrophoresis was performed on 12% acrylamide gels in
Tris/glycine buffer (27). Proteins were transferred to nitrocellulose
sheets, and blots were developed with secondary antibodies coupled to
alkaline phosphatase (Sigma); immunoreactive bands were detected with
5-bromo-4-chloro-3-indolyl phosphate (0.15 mg/ml) and nitro blue
tetrazolium (0.3 mg/ml) in 40 mM sodium carbonate and 5 mM MgCl2 (pH 9.8). In some experiments, blots were developed with secondary antibodies coupled to horseradish peroxidase (Amersham Pharmacia Biotech), and immunoreactive bands were
revealed with the ECL system (Amersham Pharmacia Biotech).
Antibodies--
Mouse monoclonal antibodies against Rac1
(Transduction Laboratories) were used at 1:500 dilution. Mouse
monoclonal antibodies against RhoA (Santa Cruz Biotechnology) were used
at 1:50 dilution. Rabbit polyclonal antibodies against RhoB and Cdc42
(Santa Cruz Biotechnology) were used at 1:50 and 1:100 dilutions,
respectively. Mouse monoclonal anti-synaptotagmin antibodies against
the C2A domain (clone 1D12), a generous gift from Dr. Masami Takahashi (Mitsubishi Kasei Institute, Tokyo, Japan), were diluted 1:1000. Rabbit
antibodies against the cytosolic epitope EQEGYQPNYGQ of synaptophysin
(28) were kindly provided by Dr. Nicolas Morel (Laboratoire de
Neurobiologie Cellulaire, CNRS, Gif-sur-Yvette, France) and utilized at
1:1000 and 1:2000 dilutions.
ACh Release and Electrical Recordings at Aplysia
Synapses--
Experiments were performed at identified cholinergic
synapses (29) in buccal ganglia of Aplysia californica
(70-120 g of body weight; Marinus Inc., CA) according to previously
published procedures (30, 31). Briefly, two presynaptic cholinergic interneurons (100-150 µm in diameter) and one postsynaptic neuron (150-200 µm in diameter) in the buccal ganglion were impaled with two glass microelectrodes (3 M KCl and
Ag/AgCl2, 2-10 megaohms). ACh release from a presynaptic
neuron was monitored by evoking an action potential at 40-s intervals.
In several experiments, 1- or 2-s trains of stimuli were generated by
using supraliminar depolarizing pulses of 5 ms separated by a
repolarizing phase of adequate duration (SMP-311 pulse generator,
Bio-Logic S. A., Grenoble, France).
ACh release was estimated by measuring the amplitude of the evoked
postsynaptic current (at these synapses, it is a Cl
current) using a conventional two-electrode voltage-clamp technique and
subsequently converting it to an apparent membrane conductance by
taking into account the null potential for Cl
(i.e. the reversal potential of the postsynaptic response).
The holding potential of the postsynaptic neuron was maintained at 30 mV above ECl .
Dissected buccal ganglia were maintained at 22 °C using a Peltier
plate system and superfused continuously (50 ml/h) with a physiological
control medium containing NaCl (460 mM), KCl (10 mM), CaCl2 (33 mM),
MgCl2 (50 mM), and MgSO4 (28 mM) in 10 mM Tris-HCl (pH 7.5). This
dication-rich medium has a high
[Ca2+]/[Mg2+] ratio (0.42) to minimize
fluctuations in evoked ACh release due to spontaneous neuron firing
activity. To modify the extracellular CaCl2 concentration,
the respective concentrations of CaCl2 and MgCl2 were calculated according to the following equations:
[CaCl2] (mM) = Q(83 + [MgSO4])/(Q + 1) and [MgCl2]
(mM) = 83 [CaCl2], where
Q is the [Ca2+]/[Mg2+] ratio.
When CdCl2 (Sigma) was used, it was added directly to the
control medium. To reduce the intracellular concentration of
Ca2+ ions, EGTA was applied intraneuronally by pressure
injection (see below). Possible intracellular pH changes were avoided
by preparing EGTA in Tris-HCl (pH 7.4) with a 2.2-fold excess of Tris base.
Application of Toxins to Neurons--
To limit the toxin action
to a given neuron without modifying ACh release by a change in the ACh
receptor efficiency, toxins were microinjected into presynaptic
neurons. The sample to be injected was mixed with a vital dye (10%
(v/v) fast green; Sigma). The samples were air pressure-injected under
visual and electrophysiological monitoring. The injected volume was in
the range of 1% of the cell body volume. Following intracellular
injection, only neurons with membrane potentials of 60 to 45 mV and
with no alterations in the action potentials were utilized.
Other Methods--
Unless indicated, data are presented as
mean ± S.D. Statistical significance of the data was calculated
by paired or unpaired t tests.
 |
RESULTS |
Subcellular Distribution of Rho-related Proteins in Synaptic
Terminals--
The intracellular distribution of Rho proteins in
presynaptic terminals was investigated in synaptosomes prepared from
rat brains since the amount of neuronal tissue that can be collected from Aplysia does not allow subcellular fractionation. Fig.
1 shows a Western blot analysis of the
soluble and membrane-bound fractions obtained from purified
synaptosomes by hypotonic lysis. Using specific antibodies raised
against various members of the Rho family, we found that RhoA, RhoB,
Rac1, and Cdc42 were present in the presynaptic terminals. In contrast
to RhoA, which was largely cytosolic, and Cdc42, which was present in
both cytosolic and membrane-bound fractions, RhoB and Rac1 were mostly
detected in the particulate fraction containing synaptosomal plasma
membrane, mitochondria, large dense-core particles, and a huge amount
of synaptic vesicles. To probe the direct association of Rho proteins with the membrane of synaptic vesicles, crude synaptic vesicles obtained by high speed centrifugation (see "Experimental
Procedures") were further fractionated on a 50-800 mM
sucrose velocity gradient. Fig. 2 shows
the distribution of two synaptic vesicle marker proteins estimated by
immunoreplica analysis in the fractions collected from the sucrose
gradient. Synaptic vesicles were distributed in fractions 7-18 as
revealed by the immunosignal for synaptophysin and synaptotagmin.
Fractions 7-18 were also labeled with anti-RhoB and anti-Rac1
antibodies (Fig. 2B), suggesting that RhoB and Rac1 may
associate with the membrane of synaptic vesicles. Accordingly, previous
reports suggested the presence of several low molecular mass
GTP-binding proteins in brain synaptic vesicles (32) and cholinergic
vesicles from the electric organ of marine ray (33). Note that RhoB
and, to a certain extent, Rac1 were present in larger amounts in
fractions 15-18 (Fig. 2B). These higher density fractions
also displayed some immunoreactivity with antibodies raised against
RhoA and Cdc42, thereby revealing some heterogeneity of the vesicle
population with respect to the presence of Rho GTPases. Therefore, the
association of monomeric GTPases on synaptic vesicles was further
probed in vesicle preparations obtained by controlled-pore glass
chromatography (26). As illustrated in Fig. 2C, we detected
an immunosignal only for Rac1 in highly purified synaptic vesicles,
indicating that Rac1 is the sole member of the Rho family associated
with the membrane of synaptic vesicles.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 1.
Immunochemical detection of Rho-related
proteins in subcellular fractions from brain synaptosomes. Brain
synaptosomes were lysed by hypotonic shock and processed to separate
the cytosol, the membrane-bound compartment, and the crude synaptic
vesicle fraction. A, protein (10 µg) from total
synaptosomes (Sy), synaptosomal membranes (Sy
Mb), or the cytosol was subjected to gel electrophoresis and
immunodetection on nitrocellulose sheets using monoclonal anti-RhoA and
anti-Rac1 antibodies and polyclonal anti-RhoB and anti-Cdc42
antibodies. B and C, shown are the results from
the quantitative analysis of the distribution of Rho proteins in
synaptosomes. B, total protein content; C, Rho
protein content estimated by immunodetection on nitrocellulose and
scanning densitometry analysis. In B and C, the
values correspond to the distribution of proteins and Rho
immunoreactivity relative to the total amount detected in the
synaptosomal lysates. Similar results were obtained in two separate
experiments.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
Rac1 is associated with purified synaptic
vesicles. A, total protein profile of fractions
collected from a sucrose velocity gradient layered with the crude
synaptic vesicle fraction; B, immunoblot analysis of
synaptic vesicle markers and Rho proteins in each fraction of the
gradient (10 µg of protein/lane); C, immunoblot analysis
of synaptic vesicles purified by permeation chromatography on a
controlled-pore glass column (CPG).
|
|
Effect of Clostridial Toxins That Inactivate Rho-related Proteins
on Evoked ACh Release--
In the buccal ganglion of
Aplysia, two identified presynaptic neurons make cholinergic
synapses with the same postsynaptic neuron (29, 31). Thus, ACh release
from presynaptic neurons can be monitored by measuring the amplitude of
the evoked transmembrane current in the postsynaptic neuron. To
probe the role of Rho-related GTPases in neurotransmitter
release, we used ToxB, which specifically glucosylates Rac, Cdc42, and
Rho (34); LT, which glucosylates Rac, but has no effect on Rho and
Cdc42 (25); and C3, which ADP-ribosylates RhoA, RhoB, RhoC, and
Aplysia Rho (35, 36) and, under certain circumstances, Rac
(35, 37-39). Glucosylation or ADP-ribosylation in the effector domain
of the various Rho, Rac, and Cdc42 isoforms disrupts their interaction
with downstream effectors and thereby inactivates the intracellular
pathways controlled by these GTPases. ToxB, LT, or C3 was
pressure-injected into one presynaptic neuron, and the second
presynaptic neuron was injected with the buffer used for toxin
injection. In this way, we had an internal control for the stability of
evoked neuroexocytosis for the duration of the experiments (up to
24 h). As shown in Fig. 3, all three
toxins inhibited ACh release. More important, neither the action
potential that triggers ACh release at nerve terminals nor the
transmembrane resting potential and the membrane resistance of the
injected neurons were significantly modified after injection of the
toxins (data not shown). Therefore, the inhibition of ACh release
induced by LT, ToxB, or C3 is not due to a modification of membrane
excitability. The mean inhibition induced by the three toxins,
calculated 3 and 20 h after injection, is shown in Fig.
3B. The three toxins induced an almost complete inhibition
of neurotransmitter release 20 h after injection (Fig. 3B). Note, however, that high doses of C3 (2 µM final intraneuronal concentration) were required to
abolish neurotransmission (Fig. 3B). Collectively, these
results suggest that Rac is the most likely candidate to regulate a
rate-limiting step of exocytosis in neurons since it is the sole GTPase
inhibited by LT, ToxB, and high concentrations of C3.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
Inhibition of evoked ACh release by
clostridial toxins inactivating Rho-related GTPases. A,
ACh release was evoked every 40 s at identified synapses in the
buccal ganglion of A. californica. See the inset
for a schematic drawing of the neuronal connections. The amplitude of
the postsynaptic responses was averaged for periods of 10 min
(mean ± S.D. of 15 measurements) and plotted against time, before
and after pressure injection of LT into one of the two presynaptic
cholinergic neurons ( ). The final concentration of LT in the cell
body was ~50 nM. The second presynaptic neuron ( ) was
injected with control buffer and served as an internal control of
release stability. B, shown is a comparison of the ACh
release (mean ± S.D.) 3 h (gray bars) or 20 h (black bars) after injection of LT, ToxB, or C3. The final
intrasomatic concentrations of the toxins are indicated. Release values
from control neurons not injected with toxins are denoted
(Cont.). The decrease in ACh release that was observed after
toxin injection is significant (p < 0.001) as compared
with the various controls (before injection or after 3 and 20 h);
values for control neurons at 3 and 20 h were not significantly
different from values recorded before the time of injection.
|
|
Is Rho Implicated in Neuronal Exocytosis?--
Rho isoforms can be
constitutively activated by CNF1, which catalyzes the deamidation of
glutamine 63. This residue is conserved in RhoA, RhoB, RhoC, and
Aplysia Rho. Transformation of glutamine 63 to glutamic acid
leads to inhibition of both intrinsic and Rho GTPase-activating
protein-stimulated GTPase activity of Rho proteins (22, 40). Thus, the
CNF1 action on Rho is equivalent to the amino acid substitution used to
generate dominant-positive Rho mutants. Cdc42 can also be activated by
a high concentration of this enzyme (22, 23, 40). To further evaluate
the implication of Rho and Cdc42 in neuroexocytosis, dichainal CNF1
(200 nM final intraneuronal concentration) or a CNF1
recombinant catalytic moiety (data not shown) was microinjected into
presynaptic neurons. As illustrated in Fig.
4A, no significant
modification of ACh release was observed for at least 150 min. In
longer experiments, CNF1 induced an alteration of membrane
excitability. We also examined whether Rho activation by CNF1 would be
able to restore ACh release previously inhibited by LT. LT (50 nM final concentration) was first injected into a
presynaptic neuron, and after ACh release had stabilized, CNF1 (200 nM final concentration) was injected into the same neuron.
As illustrated in Fig. 4B, CNF1 was unable to rescue the ACh
release inhibited by LT treatment. These experiments suggest that
neither Rho nor Cdc42 plays a crucial role in neurotransmitter release.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 4.
Evoked ACh release after injection of
CNF1. Experiments were performed as described in the legend to
Fig. 3. A, CNF1 purified from E. coli was
injected at a final concentration of 200 nM, which is
sufficiently high to have an effect not only on Rho, but also on Cdc42.
B, LT and CNF1 were injected at the times indicated. Their
respective intrasomatic concentrations were 50 and 200 nM.
Results are presented as described in the legend to Fig.
3A.
|
|
Effect of High Frequency Train of Stimuli on ACh Release Blocked by
Clostridial Toxins--
To further define the step in neurotransmitter
release that is controlled by Rac, we examined the effect of high
frequency stimulation on LT-induced blockage of ACh release. Trains of
stimuli were elicited at 50 Hz for 1 or 2 s. Under control
conditions, after a brief facilitation (31), ACh release declined
slightly during a train stimulus (Fig.
5A, open circles),
probably due to an imbalance between the replenishment of the readily
releasable pool of vesicles and the number of vesicles that undergo
exocytosis. In LT-injected neurons, the time course of ACh release
evoked by a 50-Hz stimulation train was greatly modified (Fig.
5A, closed circles): ACh release stabilized for
~400 ms (404 ± 70 ms, n = 46) and then
increased to reach within 1 s a level that was similar to that
observed before LT injection (Fig. 5A, compare
open and closed circles). This indicates that
LT-induced inhibition of ACh release can be almost circumvented by high
frequency stimulation. Note, however, that this recovery in response to
50-Hz trains declined after 10 h of LT-induced blockage (data not
shown). The recovery of ACh release lasted 1.5-2 s after the end of
the 50-Hz train; the synapse then returned to the blocked state with a
time constant in the range of 15-60 s (see decay of ACh release in Fig. 5C). The short duration of the recovery phase indicates
that this effect is distinct from the post-tetanic potentiation of ACh
release that can be elicited by repetitive stimuli at
Aplysia synapses and that lasts for >30 min (31). The
restoration of neurotransmission depended largely on the stimulation
frequency because 10-Hz trains after several seconds of stimulation
only partially restored the activity of LT-inhibited synapses (data not
shown). Interestingly, 50-Hz trains induced a similar recovery of ACh
release in synapses inhibited by ToxB (data not shown) or high
concentrations of C3 (Fig. 5B).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of repetitive stimulation on LT- and
C3-induced blockage of ACh release. Trains of stimuli (50 Hz for
1 s) were elicited before and after LT or C3 injection
(intrasomatic concentrations of 50 nM and 2 µM, respectively). This induced a recovery of ACh release
to control levels during the 50-Hz train (A and
B) and for a short period after the train (C).
A and B, ACh release determined during a 50-Hz
train by measuring the amplitude of individual responses induced by
each of the 50 action potentials of the train. and , ACh release
measurement made before and after toxin-induced blockage (recorded 240 min after LT injection or 1200 min after C3 injection), respectively.
For comparison, values were normalized against the ACh release induced
by the first action potential of the train illustrated under control
conditions. A similar recovery effect was observed during the 46 trains
elicited in 11 LT-injected neurons in which ACh release was blocked by
at least 70%. Note the delay (d; 404 ± 70 ms,
n = 46) indicated by the horizontal arrow.
The delay was shorter in trains evoked from C3-injected neurons
(256 ± 84 ms, n = 8), but the extent of release
blockage was smaller. C, ACh release after a 50-Hz train.
ACh exocytosis, evoked by a single stimulus every 10 s, was
monitored before (100% release in the control) and after LT had
exerted its inhibitory action (here at ~530 min after LT injection).
At the time indicated by the small arrows, 50-Hz stimulation
was elicited. ACh release was evoked 2 s after the end of the
50-Hz train (to detect near-maximal recovery) and then every 10 s.
Note the very short duration of the recovery phase. D, 50-Hz
stimulation cannot induce ACh release recovery at nerve terminals where
Ca2+ influx is reduced. A typical experiment from a series
of five is presented. ACh release during 50-Hz trains was determined in
control medium ( ) or after superfusing the preparation for 1 h
with physiological medium containing
[Ca2+]/[Mg2+] at 0.09 ( ) or 400 µM CdCl2 ( ).
|
|
To determine if this release recovery was specifically related to the
blockage induced by the inactivation of an intraneuronal GTPase, we
examined the ACh liberation during 50-Hz trains in buccal ganglia in
which ACh release had been previously depressed either by partial
inhibition of Ca2+ channels (by adding CdCl2 to
the superfusion medium) or by lowering extracellular Ca2+
to reduce Ca2+ entry. In these experiments, the
extracellular [Ca2+]/[Mg2+] ratio and
[CdCl2] were adjusted to produce a decrease in evoked ACh
release comparable to that observed 5-7 h after LT intraneuronal injection. When extracellular Ca2+ was reduced
([Ca2+]/[Mg2+] ratio = 0.09) or when
400 µM CdCl2 was present, ACh release did not
recover control amplitude during 50-Hz trains (Fig. 5D). More important, these results suggest that the blockage of ACh release
due to LT or ToxB is not comparable to an inhibition of Ca2+ influx into nerve terminals.
Recovery from LT-induced Blockage of ACh Release Requires
Ca2+ Ions--
It is well known that during repetitive
stimulation, residual cytosolic Ca2+ concentration
increases in nerve terminals. Therefore, we examined whether the
transient recovery that occurs in response to a 50-Hz stimulation was
dependent on the presence of Ca2+ ions. To test this
possibility, the Ca2+ chelator EGTA was injected at a final
concentration of 1 mM into presynaptic neurons in which ACh
release was inhibited by preinjection of LT. We found that EGTA
completely abolished the recovery of ACh release observed during 50-Hz
stimulation in LT-injected neurons (Fig.
6A, compare open
and closed circles). The calcium dependence of 50-Hz-induced
recovery was further confirmed by increasing the extracellular
Ca2+ concentration: superfusion of the preparation with a
medium containing a [Ca2+]/[Mg2+] ratio of
2.1 instead of 0.42 allowed a faster recovery of ACh release in
response to 50-Hz trains (Fig. 6B, compare delays
d1 and d2).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
Ca2+ dependence of ACh release
recovery induced by high frequency stimulation in LT-injected
neurons. A and B represent data from a
typical experiment of a series of three to five performed as described
in the legend to Fig. 5A. For comparison of the recovery
effects under the various conditions, ACh release values were
normalized against the amplitude determined at the end of the 1-s
control trains recorded in each experiment (i.e. 100%
recovery level). A, LT (50 nM in the cell body)
was injected to block ACh release. Values ( ) correspond to a 50-Hz
response recorded 332 min after LT injection. Then, 1 mM
EGTA was injected into the same neuron. Values ( ) correspond to a
typical train, recorded here 460 min after LT injection and 40 min
after EGTA intraneuronal application. B, in this experiment,
50-Hz trains were recorded 242 min after LT injection in a
physiological medium containing a
[Ca2+]/[Mg2+] ratio of 0.42 ( ) or in the
same experiment 340 min after LT injection in the presence of high
Ca2+ (physiological medium containing a
[Ca2+]/[Mg2+] ratio of 2.1) ( ).
d1 and d2 represent the delays before the
initiation of ACh recovery.
|
|
Effect of LT and C3 Injection on Paired-pulse
Facilitation--
Inhibition of ACh release by LT, ToxB, or high
concentrations of C3 may result from a diminution of either the release
probability (p) or the number of releasable vesicles
(n) docked at the plasma membrane. An easy procedure to
discriminate between p or n is to examine
paired-pulse facilitation (PPF). PPF denotes the increase in amplitude
of a second (test) response compared with a conditioning response
following two successive stimulations. PPF amplitude depends mainly on
p: a reduction of p is generally accompanied by
an increase in PPF amplitude probably due to the fractional desaturation of the release machinery (41). For instance, lowering extracellular [Ca2+] reduces p. Accordingly,
PPF was strongly increased when the [Ca2+]/[Mg2+] ratio was reduced from 0.42 to 0.14 (Fig. 7A), an
experimental condition that reduced ACh release to 28.5 ± 7%. To
accurately determine PPF amplitude, ACh release levels must be stable.
Hence, PPF protocols were elicited before and after LT or C3 injection, when ACh release was nearly stabilized. Fig. 7A shows that,
despite the reduction of ACh release to 29.8 ± 2.5% by LT or to
33.5 ± 4.5% by 2 µM C3, PPF amplitude was not
significantly modified, in contrast to the strong increase in PPF
observed in low extracellular Ca2+ (Fig. 7A).
This difference is further illustrated in an experiment performed in a
synapse in which both experimental conditions were examined: PPF was
first determined in low Ca2+ and then, after LT-induced
inhibition, in physiological calcium (Fig. 7B). Whatever the
time interval between the paired stimuli, we found that PPF was not
significantly modified by the injection of LT, although it
significantly increased when extracellular [Ca2+] was
reduced (see legend to Fig. 7B). Taken together, these
results suggest that the inhibition produced by LT or C3 injection is likely to be linked to a decrease in the number of vesicles available for release rather than to a diminution of their release
probability. Hence, a Rho-related GTPase appears to control
the size of the pool of readily releasable synaptic vesicles in
neurons.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 7.
Paired-pulse facilitation in LT-injected
neurons. Paired stimuli were given at various interpulse time
intervals in physiological medium and after stabilization of the
inhibition of ACh release produced by lowering extracellular
[Ca2+] ([Ca2+]/[Mg2+]
ratio = 0.14) or by injection of LT (50 nM, 3-5 h,
depending on the experiment). A, PPF induced by a 40-ms
interpulse interval was determined from at least 25 recordings made for
each condition in each experiment. For validity of comparison, PPF
measurements were made at similar levels of ACh inhibition (ACh release
reduced to 28.5 ± 7% in low Ca2+, to 29.8 ± 2.3% with LT, and to 33.5 ± 4.5% with 2 µM C3,
n = 4 and n = 6, 3, and 4, respectively). The facilitation increment (mean ± S.D.),
determined by subtracting control PPF from PPF calculated after
treatment, is reported. A significant difference was observed when
[Ca2+] was lowered (p < 0.0001), but not after ACh blockage by LT (p = 0.5).
B, in this representative experiment, the extent of PPF was
determined in the same neuron in the presence of low Ca2+
( ), control physiological medium ( ), and after LT (50 nM) had blocked ACh release ( ). The time course of ACh
release under these conditions is plotted in B2. In
B1, the facilitation (mean ± S.E. from 12 recordings
at each time interval) was significantly potentiated in low
Ca2+ (** denotes p < 0.001; * denotes
p < 0.01) except at an interval of 90 ms
(p > 0.05). After blockage of ACh release by LT, PPF
was not significantly increased for all intervals (p > 0.05; at 90 ms, p > 0.5).
|
|
 |
DISCUSSION |
Rac1, RhoA, RhoB, and Cdc42 Are Present in Nerve
Terminals--
The aim of this study was to determine the occurrence
of Rho-related proteins in nerve terminals and their possible
implication in neurotransmitter release. By subcellular fractionation
of rat brain and immunoblot analysis, we found that RhoA, RhoB, Rac1, and Cdc42 are present in both cytosolic and membrane-bound compartments of purified synaptosomes. In addition, we demonstrated that only Rac1
is associated with synaptic vesicles. The absence of Rho on synaptic
vesicles contrasts with the previously reported localization of RhoA on
secretory granules in pituitary (42) and chromaffin (15) cells. This
interesting difference might be related to mechanistic differences in
the regulation of synaptic vesicle and secretory granule exocytotic processes.
Are Rho GTPases Implicated in Neurotransmitter Exocytosis?--
To
investigate the role of Rho-related proteins in neurotransmitter
release, we injected into presynaptic Aplysia neurons various clostridial toxins (LT, C3, ToxB, and CNF1), which activate or
inactivate specific members of the Rho family. We found that ToxB,
which specifically glucosylates Rac, Cdc42, and Rho, but does not
modify any other GTPases of the Ras superfamily (34), and LT, which
glucosylates only Rac among the Rho-related GTPases (25), strongly
inhibited neurotransmitter release. In contrast, the Rho- and
Cdc42-activating toxin CNF1 (22, 40) had no effect on ACh release. C3
selectively ADP-ribosylates Rho isoforms at low concentrations (35,
36), but also affects Rac at high doses (35, 37-39). C3 inhibited
neurotransmission only when injected at micromolar concentrations into
the presynaptic neuron. Taken together, these observations suggest that
Rac1 may participate in the molecular machinery underlying
neurotransmitter release.
In addition to Rac, LT can also inactivate Ras (43) and, to
a much lesser extent, Rap and Ral GTPases (25). Hence, the rapid
inhibitory effect of LT compared with ToxB or C3 could indicate either
that LT is much more efficient than ToxB or C3 in neutralizing
intraneuronal Rac or that other small GTPases of the Ras superfamily
participate in neurotransmission. Consistent with this latter
possibility, Ral has been found on synaptic vesicles (33, 44), and
translocation of Rap from secretory granules to plasma membrane has
been reported (45, 46). Ras is present in neurons (33) and on
synaptosomal membranes (47). However, the specific association of the
Ras guanine nucleotide exchange factor CDC25M with postsynaptic
densities (48) suggests a postsynaptic rather than a presynaptic role
for Ras. Furthermore, it is noteworthy that LT, ToxB, and high doses of
C3 produced similar responses in our experiments, i.e. a
blockage of ACh release that could be completely suppressed in <1 s by
50-Hz trains. This suggests that the toxins interfere with
neurotransmission most likely by inactivating the same target. The only
common substrate of these three toxins is Rac. On the other hand, in
view of the cross-talk between Rac- and Ras-dependent
pathways (49, 50), we cannot completely exclude the possibility that
inactivation of Ras participates to some extent in the LT-induced
blockage of ACh release. For instance, the reduced efficiency of 50-Hz
trains to restore ACh release 10 h after LT injection may well be
due to the inactivation of both Ras and Rac.
Interestingly, functional Rac is needed for regulated exocytosis in rat
basophilic leukemia cells (13), pancreatic beta cells (12), and mast
cells (14). On the other hand, Rho is not considered to be an active
regulator of secretion (12-15), despite the finding that activated
RhoA stabilizes actin filaments around the secretory granules (15, 16).
Thus, our hypothesis that Rac1 is involved in evoked neurotransmitter
release correlates well with these data obtained in endocrine cells.
Clostridial Toxins Affect a Late Stage of Neurotransmitter
Release--
To characterize the origin of the ACh blockage induced by
LT, ToxB, or C3, we examined ACh release during high frequency or paired stimulation. The main conclusions from these experiments can be
summarized as follows. (i) Rho-related GTPases are well known
organizers of the actin-based cytoskeleton (for review, see Ref. 2).
However, the possibility that the inhibition of neurotransmission by
the toxins is due to a remodeling of the synaptic connections is very
unlikely because ACh release almost completely recovered in <1 s in
response to high frequency stimulation. (ii) In view of its rapidity,
it is rather unlikely that the recovery phase induced by repetitive
stimulation results from a transient deglucosylation/de-ADP-ribosylation of the intraneuronal target(s) modified by the toxins. (iii) The inhibitory effect of LT on
neurotransmitter release in response to a 50-Hz stimulation train was
distinguishable from the effect induced by a blockage of
Ca2+ channels. Thus, ACh blockage induced by LT, ToxB, or
high concentrations of C3 is unlikely to result from an inactivation of
Ca2+ influx. (iv) LT seems to block a
Ca2+-dependent step of neurotransmitter release
because restoration of ACh release during 50-Hz trains is
Ca2+-dependent. (v) ACh release blocked by LT,
ToxB, or high concentrations of C3 can completely recover within 1 s. This is clearly shorter than the time constant for vesicle recycling
(6 s at hippocampal synapses) (51). Thus, the synaptic vesicles
involved in the restoration of neurotransmission in response to high
frequency stimulation must already be present in the toxin-blocked
nerve terminals. (vi) Despite the fact that ACh release is strongly inhibited, paired-pulse facilitation is not significantly modified in
LT- or C3-injected neurons. Hence, the blockade of ACh release induced
by the toxins is likely to result from a decrease in the number of
readily releasable vesicles.
Taken together, these conclusions are consistent with the proposal that
the small G-protein modified by LT, ToxB, and high concentrations of C3
regulates a late Ca2+-dependent step of the
neurotransmitter exocytotic process. Interestingly, high frequency
firing has been demonstrated to allow a fast
Ca2+-dependent replenishment of the pool of
readily releasable vesicles at the calyx of Held (52). In view of this
observation, it is tempting to explain the recovery of
neurotransmission induced by 50-Hz stimulation trains by the rapid
replenishment of the readily releasable vesicle population through a
Ca2+-dependent recruitment of synaptic vesicles
that have been "frozen" close to the fusion sites, most likely by
the inactivation of Rac1.
Control of Neurotransmitter Release by Rho-related G-proteins:
Which Downstream Pathway?--
A number of observations have
implicated the Rho family in signal transduction pathways regulating
the actin cytoskeletal network (for review, see Ref. 2). Rac1 and Rho
can interact with Rho kinase (53, 54) and thereby control myosin
phosphorylation (55). Since myosin II is localized within presynaptic
terminals, where it controls neurotransmitter release (56), it is
tempting to propose that Rac1 controls neurotransmitter exocytosis by
regulating the actomyosin interactions involved in the movement of
synaptic vesicles toward the docking/fusion sites. On the other hand,
the effectors controlled by Rho-related proteins in neuroexocytosis might involve phosphoinositides. Indeed, Rac can stimulate directly several phosphatidylinositol-phosphate kinases (57, 58), and several
steps of the exocytotic process are controlled by synaptic proteins
that bind phosphoinositides. These include synaptotagmin (59),
rabphilin (60), and FYVE finger proteins (61). Thus, it becomes quite
interesting to determine whether there is cross-talk between Rac and
phosphatidylinositol-phosphate kinases during exocytosis at the nerve terminals.
To conclude, this report demonstrates for the first time that a common
target for LT, ToxB, and C3 clostridial toxins, most likely Rac1,
controls a late stage of Ca2+-dependent
neuroexocytosis. Further integration of Rac1 in the pathway of
neuroexocytosis now awaits the elucidation of its mechanism of
activation and the identification of its downstream molecular effectors
in the synapse.
 |
ACKNOWLEDGEMENTS |
We thank Dr. A. Feltz for critically reading
the manuscript, Dr. N. Grant for revising the manuscript, and A.-S
Caumont for help in experiments. We gratefully acknowledge
Drs. M. F. Diebler, N. Morel, and G. Schiavo for advice on
synaptosomal fractionation. We are indebted to Drs. F. Benfenati and F. Onofri for help in synaptic vesicle purification. We thank Dr. Masami
Takahashi for the generous gift of anti-synaptotagmin antibodies and
Dr. N. Morel for kindly providing anti-synaptophysin antibodies.
 |
FOOTNOTES |
*
This work was supported by grants from the Association
Française contre les Myopathies and the Programme de Recherche
Fondamentale en Microbiologie et Maladies Infectieuses et Parasitaires
and by Direction des Systèmes des Forces et de la Prospective
Contract 99-34-038 (to B. P.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Dept. of Neurobiology, Duke University Medical
Center, Durham, 27710 NC.
Present address: Dipt. di Farmacologia e Fisiologia Umana,
Facoltà di Medicina e Chirurgia, Università di Bari,
I-70124 Bari, Italy.
§§
To whom correspondence should be addressed: Lab. de Neurobiologie
Cellulaire, CNRS, 5 rue Blaise Pascal, F-67084 Strasbourg Cédex,
France. Tel.: 33-3-88-45-66-77; Fax: 33-3-88-60-16-64; E-mail:
poulain@neurochem.u-strasbg.fr.
 |
ABBREVIATIONS |
The abbreviations used are:
ACh, acetylcholine;
LT, lethal toxin;
CNF1, cytotoxic necrotizing factor 1;
ToxB, toxin B;
PPF, paired-pulse facilitation.
 |
REFERENCES |
| 1.
|
Symons, M.
(1996)
Trends Biochem. Sci.
21,
178-181[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Hall, A.
(1998)
Science
279,
509-514[Abstract/Free Full Text]
|
| 3.
|
Ren, X. D.,
and Schwartz, M. A.
(1998)
Curr. Opin. Genet. Dev.
8,
63-67[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Martin, T. F
(1994)
Curr. Opin. Neurobiol.
4,
626-632[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Südhof, T. C.
(1995)
Nature
375,
645-653[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Calakos, N.,
and Scheller, R. H.
(1996)
Physiol. Rev.
76,
1-29[Abstract/Free Full Text]
|
| 7.
|
Morgan, A.,
and Burgoyne, R. D.
(1997)
Semin. Cell Dev. Biol.
8,
141-149[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Fernandez-Chacon, R.,
and Südhof, T. C.
(1999)
Annu. Rev. Physiol.
61,
753-776[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Geppert, M.,
and Südhof, T. C.
(1998)
Annu. Rev. Neurosci.
21,
75-95[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Bajjalieh, S. M.
(1999)
Curr. Opin. Neurobiol.
9,
321-328[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Edwards, R. H.
(1998)
Curr. Biol.
8,
883-885
|
| 12.
|
Kowluru, A.,
Li, G.,
Rabaglia, M. E.,
Segu, V. B.,
Hofmann, F.,
Aktories, K.,
and Metz, S. A.
(1997)
Biochem. Pharmacol.
54,
1097-1108[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Prepens, U.,
Just, I.,
von Eichel-Streiber, C.,
and Aktories, K.
(1996)
J. Biol. Chem.
271,
7324-7329[Abstract/Free Full Text]
|
| 14.
|
Brown, A. M.,
O'Sullivan, A. J.,
and Gomperts, B. D.
(1998)
Mol. Biol. Cell
9,
1053-1063[Abstract/Free Full Text]
|
| 15.
|
Gasman, S.,
Chasserot-Golaz, S.,
Hubert, P.,
Aunis, D.,
and Bader, M.-F.
(1998)
J. Biol. Chem.
273,
16913-16920[Abstract/Free Full Text]
|
| 16.
|
Gasman, S.,
Chasserot-Golaz, S.,
Popoff, M. R.,
Aunis, D.,
and Bader, M.-F.
(1997)
J. Biol. Chem.
272,
20564-20571[Abstract/Free Full Text]
|
| 17.
|
Luo, L.,
Jan, L. Y.,
and Jan, Y. N.
(1997)
Curr. Opin. Neurobiol.
7,
81-86[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Aktories, K.
(1997)
Trends Microbiol.
5,
282-288[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Popoff, M. R.
(1987)
Infect. Immun.
55,
35-43[Abstract/Free Full Text]
|
| 20.
|
Popoff, M. R.,
Hauser, D.,
Boquet, P.,
Eklund, M. W.,
and Gill, D. M.
(1991)
Infect. Immun.
59,
3673-3679[Abstract/Free Full Text]
|
| 21.
|
Marvaud, J. C.,
Gibert, M.,
Inoue, K.,
Fujinaga, Y.,
Oguma, K.,
and Popoff, M. R.
(1998)
Mol. Microbiol.
29,
1009-1018[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Flatau, G.,
Lemichez, E.,
Gauthier, M.,
Chardin, P.,
Paris, S.,
Fiorentini, C.,
and Boquet, P.
(1997)
Nature
387,
729-733[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Fiorentini, C.,
Fabbri, A.,
Flatau, G.,
Donelli, G.,
Matarrese, P.,
Lemichez, E.,
Falzano, L.,
and Boquet, P.
(1997)
J. Biol. Chem.
272,
19532-19537[Abstract/Free Full Text]
|
| 24.
|
Lemichez, E.,
Flatau, G.,
Bruzzone, M.,
Boquet, P.,
and Gauthier, M.
(1997)
Mol. Microbiol.
24,
1061-1070[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Popoff, M. R.,
Chaves-Orlate, E.,
Lemichez, E.,
von Eichel-Streiber, C.,
Thelestam, M.,
Chardin, P.,
Cussac, D.,
Antonny, B.,
Chavrier, P.,
Flatau, G.,
Giry, M.,
de Gunzburg, J.,
and Boquet, P
(1996)
J. Biol. Chem.
271,
10217-10224[Abstract/Free Full Text]
|
| 26.
|
Huttner, W. B.,
Schiebler, W.,
Greengard, P.,
and De Camilli, P.
(1983)
J. Cell Biol.
96,
1374-1388[Abstract/Free Full Text]
|
| 27.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Taubenblatt, P.,
Dedieu, J. C.,
Gulik-Krzywicki, T.,
and Morel, N.
(1999)
J. Cell Sci.
112,
3559-3567[Abstract]
|
| 29.
|
Gardner, D.
(1971)
Science
173,
550-553[Abstract/Free Full Text]
|
| 30.
|
Johannes, L.,
Doussau, F.,
Clabecq, A.,
Henry, J.-P.,
Darchen, F.,
and Poulain, B.
(1996)
J. Cell Sci.
109,
2875-2884[Abstract]
|
| 31.
|
Doussau, F.,
Clabecq, A.,
Henry, J.-P.,
Darchen, F.,
and Poulain, B.
(1998)
J. Neurosci.
18,
3147-3157[Abstract/Free Full Text]
|
| 32.
|
Matsuoka, I.,
and Dolly, J. O.
(1990)
Biochim. Biophys. Acta
1026,
99-104[Medline]
[Order article via Infotrieve]
|
| 33.
|
Ngsee, J. K.,
Elferink, L. A.,
and Scheller, R. H.
(1991)
J. Biol. Chem.
266,
2675-2680[Abstract/Free Full Text]
|
| 34.
|
Just, I.,
Selzer, J.,
Wilm, M.,
von Eichel-Streiber, C.,
Mann, M.,
and Aktories, K.
(1995)
Nature
375,
500-503[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Quilliam, L. A.,
Lacal, J. C.,
and Bokoch, G. M.
(1989)
FEBS Lett.
247,
221-226[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Sekine, A.,
Fujiwara, M.,
and Narumiya, S.
(1989)
J. Biol. Chem.
264,
8602-8605[Abstract/Free Full Text]
|
| 37.
|
Didsbury, J.,
Weber, R. F.,
Bokoch, G. M.,
Evans, T.,
and Snyderman, R.
(1989)
J. Biol. Chem.
264,
16378-16382[Abstract/Free Full Text]
|
| 38.
|
Just, I.,
Mohr, C.,
Schallehn, G.,
Menard, L.,
Didsbury, J. R.,
Vandekerckhove, J.,
van Damme, J.,
and Aktories, K.
(1992)
J. Biol. Chem.
267,
10274-10280[Abstract/Free Full Text]
|
| 39.
|
Menard, L.,
Tomhave, E.,
Casey, P. J.,
Uhing, R. J.,
Snyderman, R.,
and Didsbury, J. R.
(1992)
Eur. J. Biochem.
206,
537-546[Medline]
[Order article via Infotrieve]
|
| 40.
|
Schmidt, G.,
Sehr, P.,
Wilm, M.,
Selzer, J.,
Mann, M.,
and Aktories, K.
(1997)
Nature
387,
725-729[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Mallart, A.,
and Martin, A. R.
(1967)
J. Physiol. (Lond.)
193,
593-604
|
| 42.
|
Cussac, D.,
Leblanc, P.,
L'Heritier, A.,
Bertoglio, J.,
Lang, P.,
Kordon, C.,
Enjalbert, A.,
and Saltarelli, D.
(1996)
Mol. Cell. Endocrinol.
119,
195-206[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Just, I.,
Selzer, J.,
Hofmann, F.,
Green, G. A.,
and Aktories, K.
(1996)
J. Biol. Chem.
271,
10149-10153[Abstract/Free Full Text]
|
| 44.
|
Volknandt, W.,
Pevsner, J.,
Elferink, L. A.,
and Scheller, R. H.
(1993)
FEBS Lett.
317,
53-56[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Maridonneau-Parini, I.,
and de Gunzburg, J.
(1992)
J. Biol. Chem.
267,
6396-6402[Abstract/Free Full Text]
|
| 46.
|
D'Silva, N. J.,
Jacobson, K. L.,
Ott, S. M.,
and Watson, E. L.
(1998)
Am. J. Physiol.
274,
C1667-C1673[Abstract/Free Full Text]
|
| 47.
|
Kim, S.,
Mizoguchi, A.,
Kikuchi, A.,
and Takai, Y.
(1990)
Mol. Cell. Biol.
10,
2645-2652[Abstract/Free Full Text]
|
| 48.
|
Sturani, E.,
Abbondio, A.,
Branduardi, P.,
Ferrari, C.,
Zippel, R.,
Martegani, E.,
Vanoni, M.,
and Denis-Donini, S.
(1997)
Exp. Cell Res.
235,
117-123[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Ridley, A. J.,
and Hall, A.
(1992)
Cell
70,
389-399[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Ridley, A. J.,
Paterson, H. F.,
Johnston, C. L.,
Diekmann, D.,
and Hall, A.
(1992)
Cell
70,
401-410[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Klingauf, J.,
Kavalali, E. T.,
and Tsien, R. W.
(1998)
Nature
394,
581-585[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Wang, L. Y.,
and Kaczmarek, L. K.
(1998)
Nature
394,
384-388[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Madaule, P.,
Furuyashiki, T.,
Reid, T.,
Ishizaki, T.,
Watanabe, G.,
Morii, N.,
and Narumiya, S.
(1995)
FEBS Lett.
377,
243-248[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Lamarche, N.,
Tapon, N.,
Stowers, L.,
Burbelo, P. D.,
Aspenstrom, P.,
Bridges, T.,
Chant, J.,
and Hall, A.
(1996)
Cell
87,
519-529[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Amano, M.,
Ito, M.,
Kimura, K.,
Fukata, Y.,
Chihara, K.,
Nakano, T.,
Matsuura, Y.,
and Kaibuchi, K.
(1996)
J. Biol. Chem.
271,
20246-20249[Abstract/Free Full Text]
|
| 56.
|
Mochida, S.,
Kobayashi, H.,
Matsuda, Y.,
Yuda, Y.,
Muramoto,
and Nonomura, Y.
(1994)
Neuron
13,
1131-1142[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Hartwig, J. H.,
Bokoch, G. M.,
Carpenter, C. L.,
Janmey, P. A.,
Taylor, L. A.,
Toker, A.,
and Stossel, T. P
(1995)
Cell
82,
643-653[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Bokoch, G. M.,
Vlahos, C. J,
Wang, Y.,
Knaus, U. G.,
and Traynor-Kaplan, A. E.
(1996)
Biochem. J.
315,
775-779
|
| 59.
|
Schiavo, G.,
Gu, Q. M.,
Prestwich, G. D.,
Söllner, T. H.,
and Rothman, J. E.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
13327-13332[Abstract/Free Full Text]
|
| 60.
|
Miyazaki, M.,
Kaibuchi, K.,
Shirataki, H.,
Kohno, H.,
Ueyama, T.,
Nishikawa, J.,
and Takai, Y.
(1995)
Brain Res. Mol. Brain Res.
28,
29-36[Medline]
[Order article via Infotrieve]
|
| 61.
|
Bean, A. J.,
Seifert, R.,
Chen, Y. A.,
Sacks, R.,
and Scheller, R. H.
(1997)
Nature
385,
826-829[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
F. Momboisse, E. Lonchamp, V. Calco, M. Ceridono, N. Vitale, M.-F. Bader, and S. Gasman
{beta}PIX-activated Rac1 stimulates the activation of phospholipase D, which is associated with exocytosis in neuroendocrine cells
J. Cell Sci.,
March 15, 2009;
122(6):
798 - 806.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. McMullan and S. J. Nurrish
Rho deep in thought
Genes & Dev.,
November 1, 2007;
21(21):
2677 - 2682.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. B. Fernandes, P. J. Henry, and R. G. Goldie
Review: Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease
Therapeutic Advances in Respiratory Disease,
October 1, 2007;
1(1):
25 - 33.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Pochynyuk, A. Staruschenko, V. Bugaj, L. LaGrange, and J. D. Stockand
Quantifying RhoA Facilitated Trafficking of the Epithelial Na+ Channel toward the Plasma Membrane with Total Internal Reflection Fluorescence-Fluorescence Recovery after Photobleaching
J. Biol. Chem.,
May 11, 2007;
282(19):
14576 - 14585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kajimoto, T. Okada, H. Yu, S. K. Goparaju, S. Jahangeer, and S.-i. Nakamura
Involvement of Sphingosine-1-Phosphate in Glutamate Secretion in Hippocampal Neurons
Mol. Cell. Biol.,
May 1, 2007;
27(9):
3429 - 3440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Pochynyuk, J. Medina, N. Gamper, H. Genth, J. D. Stockand, and A. Staruschenko
Rapid Translocation and Insertion of the Epithelial Na+ Channel in Response to RhoA Signaling
J. Biol. Chem.,
September 8, 2006;
281(36):
26520 - 26527.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Rajnicek, L. E. Foubister, and C. D. McCaig
Temporally and spatially coordinated roles for Rho, Rac, Cdc42 and their effectors in growth cone guidance by a physiological electric field
J. Cell Sci.,
May 1, 2006;
119(9):
1723 - 1735.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Bi, S. L. Page, and J. A. Williams
Rho and Rac promote acinar morphological changes, actin reorganization, and amylase secretion
Am J Physiol Gastrointest Liver Physiol,
September 1, 2005;
289(3):
G561 - G570.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Bi and J. A. Williams
A role for Rho and Rac in secretagogue-induced amylase release by pancreatic acini
Am J Physiol Cell Physiol,
July 1, 2005;
289(1):
C22 - C32.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Ishida, X. Zhang, K. Erickson, and P. Ray
Botulinum Toxin Type A Targets RhoB to Inhibit Lysophosphatidic Acid-Stimulated Actin Reorganization and Acetylcholine Release in Nerve Growth Factor-Treated PC12 Cells
J. Pharmacol. Exp. Ther.,
September 1, 2004;
310(3):
881 - 889.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Barbier, M. R. Popoff, and J. Molgo
Degeneration and Regeneration of Murine Skeletal Neuromuscular Junctions after Intramuscular Injection with a Sublethal Dose of Clostridium sordellii Lethal Toxin
Infect. Immun.,
June 1, 2004;
72(6):
3120 - 3128.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Li, R. Luo, A. Kowluru, and G. Li
Novel regulation by Rac1 of glucose- and forskolin-induced insulin secretion in INS-1 {beta}-cells
Am J Physiol Endocrinol Metab,
May 1, 2004;
286(5):
E818 - E827.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gasman, S. Chasserot-Golaz, M. Malacombe, M. Way, and M.-F. Bader
Regulated Exocytosis in Neuroendocrine Cells: A Role for Subplasmalemmal Cdc42/N-WASP-induced Actin Filaments
Mol. Biol. Cell,
February 1, 2004;
15(2):
520 - 531.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Li, C. S Ho, V. Marinescu, H. Bhatti, G. M Bokoch, S. A Ernst, R. W Holz, and E. L Stuenkel
Facilitation of Ca2+-dependent exocytosis by Rac1-GTPase in bovine chromaffin cells
J. Physiol.,
July 15, 2003;
550(2):
431 - 445.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Camacho and R. Malho
Endo/exocytosis in the pollen tube apex is differentially regulated by Ca2+ and GTPases
J. Exp. Bot.,
January 1, 2003;
54(380):
83 - 92.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Hobert, K. A. Sands, R. J. Mrsny, and J. L. Madara
Cdc42 and Rac1 Regulate Late Events in Salmonella typhimurium-induced Interleukin-8 Secretion from Polarized Epithelial Cells
J. Biol. Chem.,
December 20, 2002;
277(52):
51025 - 51032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Pi, R. F. Spurney, Q. Tu, T. Hinson, and L. D. Quarles
Calcium-Sensing Receptor Activation of Rho Involves Filamin and Rho-Guanine Nucleotide Exchange Factor
Endocrinology,
October 1, 2002;
143(10):
3830 - 3838.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Humeau, M. R. Popoff, H. Kojima, F. Doussau, and B. Poulain
Rac GTPase Plays an Essential Role in Exocytosis by Controlling the Fusion Competence of Release Sites
J. Neurosci.,
September 15, 2002;
22(18):
7968 - 7981.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Le Cabec, S. Carreno, A. Moisand, C. Bordier, and I. Maridonneau-Parini
Complement Receptor 3 (CD11b/CD18) Mediates Type I and Type II Phagocytosis During Nonopsonic and Opsonic Phagocytosis, Respectively
J. Immunol.,
August 15, 2002;
169(4):
2003 - 2009.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Carreno, E. Caron, C. Cougoule, L. J. Emorine, and I. Maridonneau-Parini
p59Hck Isoform Induces F-actin Reorganization to Form Protrusions of the Plasma Membrane in a Cdc42- and Rac-dependent Manner
J. Biol. Chem.,
May 31, 2002;
277(23):
21007 - 21016.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Humeau, N. Vitale, S. Chasserot-Golaz, J.-L. Dupont, G. Du, M. A. Frohman, M.-F. Bader, and B. Poulain
A role for phospholipase D1 in neurotransmitter release
PNAS,
December 18, 2001;
98(26):
15300 - 15305.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Vazquez-Martinez, S. L. Shorte, W. J. Faught, D. C. Leaumont, L. S. Frawley, and F. R. Boockfor
Pulsatile Exocytosis Is Functionally Associated with GnRH Gene Expression in Immortalized GnRH-Expressing Cells
Endocrinology,
December 1, 2001;
142(12):
5364 - 5370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Qa'Dan, L. M. Spyres, and J. D. Ballard
pH-Enhanced Cytopathic Effects of Clostridium sordellii Lethal Toxin
Infect. Immun.,
September 1, 2001;
69(9):
5487 - 5493.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Humeau, F. Doussau, F. Vitiello, P. Greengard, F. Benfenati, and B. Poulain
Synapsin Controls Both Reserve and Releasable Synaptic Vesicle Pools during Neuronal Activity and Short-Term Plasticity in Aplysia
J. Neurosci.,
June 15, 2001;
21(12):
4195 - 4206.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|